Opus Genetics, Inc. (IRD) - Form 8-K Summary
Business Context and Reporting Period
Opus Genetics, Inc., formerly known as Ocuphire Pharma, Inc., filed this Current Report on Form 8-K on November 12, 2024. The filing announces the Company's financial results for the third quarter ended September 30, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "IRD."
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing text. The filing text does not provide a clear value for these metrics.
Material Changes
No material changes versus the prior comparable period are detailed in this specific document text, as the quantitative results are contained within the referenced press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It further states that this information shall not be deemed incorporated by reference in any other filing unless expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 12, 2024) for actual Q3 2024 financial figures.
- Verify the Company's name change from Ocuphire Pharma, Inc. to Opus Genetics, Inc.
- Confirm the trading symbol "IRD" on The Nasdaq Stock Market LLC.
- Note that the financial data in this 8-K is furnished, not filed, and may not be incorporated by reference in other documents.